Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Payables (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Payables for 8 consecutive years, with $296000.0 as the latest value for Q4 2025.

  • Quarterly Payables fell 77.44% to $296000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $296000.0 through Dec 2025, down 77.44% year-over-year, with the annual reading at $296000.0 for FY2025, 77.44% down from the prior year.
  • Payables for Q4 2025 was $296000.0 at Precision Biosciences, down from $1.3 million in the prior quarter.
  • The five-year high for Payables was $3.0 million in Q4 2023, with the low at $296000.0 in Q4 2025.
  • Average Payables over 5 years is $948750.0, with a median of $860500.0 recorded in 2022.
  • The sharpest move saw Payables skyrocketed 354.52% in 2023, then tumbled 77.44% in 2025.
  • Over 5 years, Payables stood at $1.1 million in 2021, then tumbled by 42.92% to $653000.0 in 2022, then soared by 354.52% to $3.0 million in 2023, then plummeted by 55.8% to $1.3 million in 2024, then crashed by 77.44% to $296000.0 in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $296000.0, $1.3 million, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.